Thyreos Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $1.6M

  • Investors
  • 7

Thyreos General Information

Description

Operator of a biotech company intended to produce effective prophylactic human health and animal vaccines to treat herpesvirus, recombinant vaccine vectors and oncolytic vectors. The company's new technology is based on a recombinant herpesvirus platform for developing cures to prevent nervous system infections, recurrent disease and produce sterilizing immunity in humans, companion animals, and livestock, enabling doctors to treat viruses and avoid recurrences.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2125 Transformation Drive
  • Suite 1000
  • Lincoln, NE 68505
  • United States
+1 (402)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 2125 Transformation Drive
  • Suite 1000
  • Lincoln, NE 68505
  • United States
+1 (402)

Thyreos Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Thyreos Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Grant 04-May-2023 $1.6M Completed Generating Revenue
7. Seed Round 12-Dec-2022 Completed Generating Revenue
6. Accelerator/Incubator Completed Generating Revenue
5. Grant 27-Apr-2022 Completed Generating Revenue
4. Seed Round 31-Dec-2020 Completed Generating Revenue
3. Grant 01-Dec-2020 Completed Generating Revenue
2. Accelerator/Incubator 01-Jan-2017 Completed Startup
1. University Spin-Out 01-Jan-2017 Completed Startup
To view Thyreos’s complete valuation and funding history, request access »

Thyreos Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed-2
Seed
To view Thyreos’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Thyreos Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Thyreos Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
National Institute for Allergy and Infectious Disease Government
NIH Seed Not-For-Profit Venture Capital
Invest Nebraska Venture Capital Minority
The Nebraska Department of Economic Development Government
Matter (Consulting Services (B2B)) Accelerator/Incubator
You’re viewing 5 of 7 investors. Get the full list »

Thyreos FAQs

  • When was Thyreos founded?

    Thyreos was founded in 2017.

  • Where is Thyreos headquartered?

    Thyreos is headquartered in Lincoln, NE.

  • What is the size of Thyreos?

    Thyreos has 5 total employees.

  • What industry is Thyreos in?

    Thyreos’s primary industry is Drug Discovery.

  • Is Thyreos a private or public company?

    Thyreos is a Private company.

  • What is Thyreos’s current revenue?

    The current revenue for Thyreos is .

  • How much funding has Thyreos raised over time?

    Thyreos has raised $1.75M.

  • Who are Thyreos’s investors?

    National Institute for Allergy and Infectious Disease, NIH Seed, Invest Nebraska, The Nebraska Department of Economic Development, and Matter (Consulting Services (B2B)) are 5 of 7 investors who have invested in Thyreos.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process